Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib + Cemiplimab in BRAF Wild-Type Anaplastic Thyroid Cancer
NCT07470489Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2027
- Primary completion
- Sep 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib, cemiplimab in anaplastic thyroid cancer (ATC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
zanzalintinibcemiplimab
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT07470489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470489.